Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

IVD antibodies for IHC, 5/16

  May 2016—Bio SB is offering 50 new antibodies for in vitro diagnostic applications. This generation of antibodies offers higher affinity, sensitivity, and specificity when compared with the previous generation of mouse monoclonal and polyclonal antibodies traditionally used in diagnostic immunohistochemistry applications. “Our new RBT and EP clones of rabbit monoclonal antibodies are unique reagents for cancer research and diagnostics,” Alfonso Heras, DVM, PhD, president and CEO of Bio SB, said in a statement. Among them are BRAF V600E, B7/H3,

PCR system, assay receive medical device license, 5/16

May 2016—Luminex received medical device licenses from Health Canada’s Therapeutic Products Directorate, Medical Devices Bureau, for the Aries System and Aries HSV 1&2 Assay; both were FDA cleared in October 2015 and were subsequently launched in the U.S. market.

3-D in vivo confocal microscope, 5/16

May 2016—MR Solutions’ 3-D in vivo confocal microscope for use in preclinical research provides a magnification range of up to 1,000 times, allowing researchers to examine cellular details within a live small animal, eliminating the need for a surgical biopsy.

Genomic test to predict prostate cancer progression, 5/16

ay 2016—GenomeDx Biosciences launched Decipher Biopsy, a genomic test that evaluates RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis, and cancer-specific death at the time of biopsy in men with prostate cancer.

FDA-cleared Graves’ disease assay, 5/16

May 2016—Siemens Healthcare Immulite 2000/2000 XPi TSI assay for the diagnosis of Graves’ disease is FDA cleared. The assay detects the presence of thyroid-stimulating antibodies only, is fully automated, and produces results in 65 minutes.

Mouse T- and B-lymphocyte kits, 5/16

May 2016—BD mouse T-lymphocyte and B-lymphocyte kits, protocols, and software templates for the BD Accuri C6 flow cytometer aim to simplify the identification of mouse T and B lymphocytes, their subsets, and their activation markers. The kits include fluorescent antibodies, buffer systems, and controls needed for acquisition and analysis.

Digital pathology scanner, 5/16

May 2016—Leica Biosystems introduced the Aperio Versa, a combination digital pathology research scanner for bright-field, fluorescence, and FISH imaging. High levels of automation and an optional 200-slide autoloader enable unsupervised batch processing, from low magnification to high resolution, oil-immersion scanning.

MARKETPLACE

TRENDING